Global Healthcare Analyst

Tina Banerjee

Thematic (Sector/Industry)

<ul>
<li>CSPC Pharmaceutical’s Phase 3 trial of depression drug candidate HA1406 met pre-specified primary efficacy endpoint. Jiangsu Hengrui Pharmaceuticals received NMPA approval for long-acting basal insulin, sudelidec injection.</li>
<li>Otsuka Holdings secured FDA approval for Simtriyo, a once-daily extended-release capsule for ADHD. Nippon Shinyaku obtained exclusive commercialization rights for Tadekinig alfa in the U.S. for Hyperinflammatory Syndrome.</li>
<li>Pharmaessentia announced topline results from the Phase 1b clinical trial of P1101 (Besremi) and anti-PD1 in Chronic Hepatitis B or D. Cipla secured FDA approval for generic Advair Diskus.</li>
</ul>


CSPC Pharmaceutical’s Phase 3 trial of depression drug candidate HA1406 met pre-specified primary efficacy endpoint. Jiangsu Hengrui Pharmaceuticals received NMPA approval for long-acting basal insulin, sudelidec injection.
Otsuka Holdings secured FDA approval for Simtriyo, a once-daily extended-release capsule for ADHD. Nippon Shinyaku obtained exclusive commercialization rights for Tadekinig alfa in the U.S. for Hyperinflammatory Syndrome.
Pharmaessentia announced topline results from the Phase 1b clinical trial of P1101 (Besremi) and anti-PD1 in Chronic Hepatitis B or D. Cipla secured FDA approval for generic Advair Diskus.


APAC Healthcare Weekly (August 2) – CSPC, Hengrui, Otsuka, Nippon Shinyaku, PharmaEssnetia, Cipla

India Equity Analyst - Fundamental & Thematic, Beat the Street

Sudarshan Bhandari

India Equity Analyst - Fundamental & Thematic

Beat the Street

Beat The Street was founded by Nimish Maheshwari and Sudarshan Bhandari, both of whom are Chartered Accountants by Profession, known for their expert analysis in the fields of Business, Sectoral analysis, and Corporate governance.

With a strong social media presence of 45,000+ Subscribers across various platforms, they are considered trusted voices in the industry. Their insights and analysis have been featured in some of India’s most prominent publications, including the Economic Times, Dalal Street Investment Journal, The Morning Context, and The Ken.

Their analysis on Bankrupt & Insolvent companies has been instrumental in saving investors from significant losses. They have a keen eye for identifying red flags and has identified exclusive redflags earlier in Vedanta, Nykaa, Dhani Services, Adani and many more.

Read Business Not Stock Prices

<ul>
<li>
Global chemical inventory levels are at decade lows, and product prices have begun stabilizing across key segments, signaling the early stages of a demand-led recovery. </li>
<li>The capex cycle is largely behind us, setting the stage for strong free cash flow generation even as select sub-segments like amines, fluorine, and pyridines see pricing and volume tailwinds. 
</li>
<li>We adopt a selective bullish view, with momentum expected in companies that have strategically aligned capex, strong product-market fit, and established global customer relationships. 
</li>
</ul>



Global chemical inventory levels are at decade lows, and product prices have begun stabilizing across key segments, signaling the early stages of a demand-led recovery. 
The capex cycle is largely behind us, setting the stage for strong free cash flow generation even as select sub-segments like amines, fluorine, and pyridines see pricing and volume tailwinds. 

We adopt a selective bullish view, with momentum expected in companies that have strategically aligned capex, strong product-market fit, and established global customer relationships. 



Thematic Report on What’s Different About the Chemical Recovery This Time?

Market & Forensics Analyst, Beat the Street

Nimish Maheshwari

Market & Forensics Analyst

Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/aether-industries-ltd" target="_blank" data-smartkarma-citation="entities:36096:1" rel="noopener">Aether Industries (AETHER IN)</a> is a high-growth specialty chemical leader pioneering complex, first-in-India chemistries for global pharmaceutical, agrochemical, and specialized industrial sectors.</li>
<li>
 Strategic shifts toward higher-margin CEM and CRAMS models contributing over 55% of revenue in FY25, significantly enhancing long-term stability and profitability.</li>
<li>Aggressive capex targets rapid capacity expansion at Site 3++ and Site 5, with multiple production blocks operational by Q4 fiscal 2026. 
</li>
</ul>



Aether Industries (AETHER IN) is a high-growth specialty chemical leader pioneering complex, first-in-India chemistries for global pharmaceutical, agrochemical, and specialized industrial sectors.

 Strategic shifts toward higher-margin CEM and CRAMS models contributing over 55% of revenue in FY25, significantly enhancing long-term stability and profitability.
Aggressive capex targets rapid capacity expansion at Site 3++ and Site 5, with multiple production blocks operational by Q4 fiscal 2026. 



Aether Industries: Leveraging Niche Expertise for Multi-Year Growth

<ul>
<li>Vinati Organics reported a 24% QoQ increase in net income, driven by strong growth in ATBS and antioxidants.</li>
<li>The company's focus on capacity expansion and product diversification positions it for sustainable growth in FY26.</li>
<li>Continued leadership in specialty chemicals and a clear Capex roadmap reinforce confidence in future growth.</li>
</ul>


Vinati Organics reported a 24% QoQ increase in net income, driven by strong growth in ATBS and antioxidants.
The company's focus on capacity expansion and product diversification positions it for sustainable growth in FY26.
Continued leadership in specialty chemicals and a clear Capex roadmap reinforce confidence in future growth.


Vinati Organics Q4 FY25 Update: Strong Growth with Robust Performance Across Key Segments

APAC IPOs & Placements, Aequitas Research

Akshat Shah

APAC IPOs & Placements

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

Dorf-Ketal Chemicals Ltd / Equity Capital Markets

<ul>
<li>
<a href="https://www.smartkarma.com/entities/dorf-ketal-chemicals-ltd" target="_blank" data-smartkarma-citation="entities:44325:1" rel="noopener">Dorf-Ketal Chemicals Ltd (998552Z IN)</a> (DKCI) is looking to raise about US$579m in its upcoming India IPO.</li>
<li>DKCI is an R&amp;D and innovation-focused global manufacturer and supplier of specialty chemicals, catering to hydrocarbons and industrial supply chains, and customers with diverse applications across various industrial segments.</li>
<li>In this note, we talk about the not-so-positive aspects of the deal.</li>
</ul>



Dorf-Ketal Chemicals Ltd (998552Z IN) (DKCI) is looking to raise about US$579m in its upcoming India IPO.
DKCI is an R&amp;D and innovation-focused global manufacturer and supplier of specialty chemicals, catering to hydrocarbons and industrial supply chains, and customers with diverse applications across various industrial segments.
In this note, we talk about the not-so-positive aspects of the deal.


Dorf-Ketal Chemicals India Pre-IPO - The Negatives - Elevated Borrowings and Tariff Uncertainty

India

Vinati Organics Limited is a prominent Indian manufacturer of specialty chemicals and organic intermediates. The company is a global leader in producing Isobutyl Benzene (IBB) and 2-Acrylamido-2-Methylpropane Sulfonic Acid (ATBS), serving pharmaceutical, agrochemical, personal care, water treatment, and polymer industries. Headquartered in Mumbai, India, the company was founded in 1989.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Vinati Organics (VO IN)

APAC Healthcare Weekly (August 2) – CSPC, Hengrui, Otsuka, Nippon Shinyaku, PharmaEssnetia, Cipla

Hengrui got NMPA approval for long-acting insulin. FDA approves Otsuka’s new CNS drug. Pharmaessentia announced positive topline result from Phase...

Tina Banerjee

Thematic Report on What’s Different About the Chemical Recovery This Time?

Global chemical inventory levels are at decade lows, signaling the early stages of a demand-led recovery. Selective bullish view on companies with...

Sudarshan Bhandari

Aether Industries: Leveraging Niche Expertise for Multi-Year Growth

Aether Industries is a high-growth specialty chemical leader focusing on complex chemistries for global sectors, with strategic shifts towards...

Nimish Maheshwari

Vinati Organics Q4 FY25 Update: Strong Growth with Robust Performance Across Key Segments

Vinati Organics sees 24% QoQ net income rise fueled by ATBS and antioxidants, with focus on capacity expansion and product diversification for...

Sudarshan Bhandari

Dorf-Ketal Chemicals India Pre-IPO - The Negatives - Elevated Borrowings and Tariff Uncertainty

Dorf-Ketal Chemicals India is looking to raise about US$579m in its upcoming India IPO. In this note, we talk about the not-so-positive aspects of...

Akshat Shah

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

APAC Healthcare Weekly (August 2) – CSPC, Hengrui, Otsuka, Nippon Shinyaku, PharmaEssnetia, Cipla

Hengrui got NMPA approval for long-acting insulin. FDA approves Otsuka’s new CNS drug. Pharmaessentia announced positive topline result from Phase...

Tina Banerjee

Thematic Report on What’s Different About the Chemical Recovery This Time?

​Global chemical inventory levels are at decade lows, signaling the early stages of a demand-led recovery. Selective bullish view on companies with...

Sudarshan Bhandari

Aether Industries: Leveraging Niche Expertise for Multi-Year Growth

​Aether Industries is a high-growth specialty chemical leader focusing on complex chemistries for global sectors, with strategic shifts towards...

Nimish Maheshwari

Vinati Organics Q4 FY25 Update: Strong Growth with Robust Performance Across Key Segments

​Vinati Organics sees 24% QoQ net income rise fueled by ATBS and antioxidants, with focus on capacity expansion and product diversification for...

Sudarshan Bhandari

Dorf-Ketal Chemicals India Pre-IPO - The Negatives - Elevated Borrowings and Tariff Uncertainty

Dorf-Ketal Chemicals India is looking to raise about US$579m in its upcoming India IPO. In this note, we talk about the not-so-positive aspects of...

Akshat Shah

Global chemical inventory levels are at decade lows, signaling the early stages of a demand-led recovery. Selective bullish view on companies with...

Aether Industries is a high-growth specialty chemical leader focusing on complex chemistries for global sectors, with strategic shifts towards...

Vinati Organics sees 24% QoQ net income rise fueled by ATBS and antioxidants, with focus on capacity expansion and product diversification for...